BioVectra has announced entering into a long term agreement with Keryx Biopharmaceuticals (NASDAQ:KERX) that will see both companies produce Ferric Citrate. Ferric Citrate is an active pharmaceutical part of Auryxia® tablets used in the treatment of two common chronic kidney diseases.
BioVectra Inc has over 45 years of manufacturing and contract development. This include partnering with Keryx to produce Ferric Citrate API. The two companies have worked together since 2003 when they started producing Ferric Citrate API. BioVectra will be in charge of preparing for the long awaited long term supply of Ferric Citrate API. The company is expected to expand the production capacity of the production plant in Canada in a bid to meet the increasing demand.
In a statement, Oliver Technow, the president of BioVectra said the partnership is an important step for the company. He said it is an example of the company’s talent, innovation and determination that has been cultivated in Canada. He added that they are very proud of serving the needs of the company’s global partners as well as the patients they serve. He added that they are much motivated to seal such an agreement of great magnitude which is expected to create more skilled jobs to the region.
On the other hand, Keryx Biopharmaceuticals Chief Business Officer Melissa Bradford-Klug said that following the recent approval of Auryxia for a second indication by the U.S. FDA, it is important that they amass enough manufacturing capacity so as to comfortably support future demand. She added that BioVectra has been engaged in the production of active pharmaceutical ingredient in Auryxia for a long period of time and they are working on advancing the partnership so as to expand the supply chain for the drug.
Keryx Biopharmaceuticals has its headquarters in Boston and is mainly engaged in the production and commercialization of highly innovative medicines which offer unique and important advantages to people with chronic kidney diseases.